Clinical bottom line
Tumor-derived extracellular vesicles (EVs) are emerging as key mediators of cancer metastasis and therapeutic resistance across multiple solid tumor types. These nanoscale vesicles facilitate intercellular communication by transferring oncogenic proteins, nucleic acids, and lipids, thereby promoting tumor cell migration, invasion, immune evasion, and drug resistance. Although still largely investigational, EVs hold promise as biomarkers for metastatic potential and treatment response, as well as novel therapeutic targets or delivery vehicles. Clinicians should be aware of this evolving field as it may inform future strategies for risk stratification and overcoming resistance in advanced solid tumors.
What the evidence shows
Tumor-derived EVs, including exosomes and microvesicles, carry diverse cargo that modulates the tumor microenvironment and distant metastatic niches. Liguori et al. (2023) provide a comprehensive review highlighting that EVs promote cancer cell migration and metastasis by transferring pro-metastatic factors such as matrix metalloproteinases, integrins, and microRNAs. These vesicles can condition pre-metastatic niches, enhancing vascular permeability and immune suppression, thereby facilitating tumor cell colonization (Liguori et al., 2023).
Multiple studies underscore the role of EVs in therapeutic resistance. For example, EVs can shuttle drug efflux pumps, anti-apoptotic proteins, and nucleic acids encoding resistance pathways between tumor cells, contributing to chemotherapy and targeted therapy failure (Basu et al., 2021). Additionally, EVs derived from endoplasmic reticulum-stressed tumor cells may carry immunogenic molecules that paradoxically could be harnessed as cancer vaccines, suggesting a dual role in tumor progression and therapy [2].
The potential of EVs as liquid biopsy biomarkers is gaining traction. Rikkert et al. (2023) discuss how tumor-derived EVs isolated from blood samples reflect tumor burden and metastatic activity, offering a minimally invasive method to monitor disease progression and therapeutic response.
Moreover, Bertolini et al. (2024) emphasize the contribution of EVs to cancer stem cell properties, which are implicated in tumor aggressiveness and relapse. Targeting EV-mediated communication may thus disrupt stemness and metastatic competence.
Caveats and uncertainty
Despite promising preclinical data, clinical translation of EV-based diagnostics and therapeutics remains in early stages. Standardization of EV isolation, characterization, and quantification methods is lacking, complicating reproducibility and interpretation across studies (Liguori et al., 2023). The heterogeneity of EV populations and cargo content also poses challenges for defining specific biomarkers or therapeutic targets.
Most evidence derives from in vitro and animal models; robust clinical trials validating the prognostic or predictive value of tumor-derived EVs in humans are sparse. The complexity of EV biogenesis and their pleiotropic effects mean that interventions targeting EVs may have unintended consequences, including impacts on normal intercellular communication.
Additionally, the dual role of EVs in promoting metastasis but also potentially stimulating anti-tumor immunity (e.g., via immunogenic EVs from stressed tumor cells) requires careful delineation to avoid counterproductive therapeutic strategies.
How this may change practice
While routine clinical use of tumor-derived EV analysis is not yet established, awareness of their role in metastasis and resistance can inform oncologists’ understanding of tumor biology and mechanisms underlying treatment failure. In the near term, EV-based liquid biopsies may complement circulating tumor DNA and cells for more comprehensive disease monitoring.
Future developments may enable EV cargo profiling to stratify patients by metastatic risk or likelihood of resistance, guiding more personalized treatment intensification or novel combination approaches. Therapeutic strategies targeting EV release, uptake, or cargo function are under investigation and could augment current systemic therapies, particularly in refractory or metastatic settings.
Clinicians should monitor ongoing clinical trials and emerging guidelines incorporating EV biomarkers or therapeutics. Integration of EV analysis with existing molecular and imaging data may enhance precision oncology paradigms.